User login
Key clinical point: Guselkumab treatment every 4 or 8 weeks (Q4W/Q8W) showed minimal clinically important improvements (MCII) in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) after the first dose and sustained disease control for up to 1 year in patients with psoriatic arthritis (PsA).
Major finding: Both guselkumab doses (Q4W and Q8W) vs placebo led to early achievement of MCII in cDAPSA (hazard ratio 1.6-1.7; all P < .0001), with higher response rates at week 4 (P < .01). Achieving early MCII in cDAPSA was associated with sustained disease control at 24 and 52 weeks (odds ratio 1.4-3.5; all P < .05).
Study details: This post hoc analysis of phase 3 trials, DISCOVER-1 and DISCOVER-2, included 1120 patients with active PsA who received guselkumab (Q4W or Q8W) or placebo with a crossover to guselkumab Q4W at week 24.
Disclosures: This study was supported by Janssen Research & Development (JRD), LLC. Four authors declared being employees or shareholders of JRD or other sources. Several authors declared having ties with various sources, including JRD.
Source: Curtis JR, Deodhar A, Soriano ER, et al. Early Improvements with guselkumab associate with sustained control of psoriatic arthritis: Post hoc analyses of two phase 3 trials. Rheumatol Ther. 2024 (Sept 11). doi: 10.1007/s40744-024-00702-0 Source
Key clinical point: Guselkumab treatment every 4 or 8 weeks (Q4W/Q8W) showed minimal clinically important improvements (MCII) in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) after the first dose and sustained disease control for up to 1 year in patients with psoriatic arthritis (PsA).
Major finding: Both guselkumab doses (Q4W and Q8W) vs placebo led to early achievement of MCII in cDAPSA (hazard ratio 1.6-1.7; all P < .0001), with higher response rates at week 4 (P < .01). Achieving early MCII in cDAPSA was associated with sustained disease control at 24 and 52 weeks (odds ratio 1.4-3.5; all P < .05).
Study details: This post hoc analysis of phase 3 trials, DISCOVER-1 and DISCOVER-2, included 1120 patients with active PsA who received guselkumab (Q4W or Q8W) or placebo with a crossover to guselkumab Q4W at week 24.
Disclosures: This study was supported by Janssen Research & Development (JRD), LLC. Four authors declared being employees or shareholders of JRD or other sources. Several authors declared having ties with various sources, including JRD.
Source: Curtis JR, Deodhar A, Soriano ER, et al. Early Improvements with guselkumab associate with sustained control of psoriatic arthritis: Post hoc analyses of two phase 3 trials. Rheumatol Ther. 2024 (Sept 11). doi: 10.1007/s40744-024-00702-0 Source
Key clinical point: Guselkumab treatment every 4 or 8 weeks (Q4W/Q8W) showed minimal clinically important improvements (MCII) in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) after the first dose and sustained disease control for up to 1 year in patients with psoriatic arthritis (PsA).
Major finding: Both guselkumab doses (Q4W and Q8W) vs placebo led to early achievement of MCII in cDAPSA (hazard ratio 1.6-1.7; all P < .0001), with higher response rates at week 4 (P < .01). Achieving early MCII in cDAPSA was associated with sustained disease control at 24 and 52 weeks (odds ratio 1.4-3.5; all P < .05).
Study details: This post hoc analysis of phase 3 trials, DISCOVER-1 and DISCOVER-2, included 1120 patients with active PsA who received guselkumab (Q4W or Q8W) or placebo with a crossover to guselkumab Q4W at week 24.
Disclosures: This study was supported by Janssen Research & Development (JRD), LLC. Four authors declared being employees or shareholders of JRD or other sources. Several authors declared having ties with various sources, including JRD.
Source: Curtis JR, Deodhar A, Soriano ER, et al. Early Improvements with guselkumab associate with sustained control of psoriatic arthritis: Post hoc analyses of two phase 3 trials. Rheumatol Ther. 2024 (Sept 11). doi: 10.1007/s40744-024-00702-0 Source